The estimated Net Worth of Joseph A Zaccagnino is at least $8.86 ezer dollars as of 13 November 2017. Joseph Zaccagnino owns over 5,000 units of Mallinckrodt Plc stock worth over $8,861 and over the last 11 years Joseph sold MNK stock worth over $0.
Joseph has made over 2 trades of the Mallinckrodt Plc stock since 2014, according to the Form 4 filled with the SEC. Most recently Joseph bought 5,000 units of MNK stock worth $106,500 on 13 November 2017.
The largest trade Joseph's ever made was buying 5,000 units of Mallinckrodt Plc stock on 13 November 2017 worth over $106,500. On average, Joseph trades about 615 units every 91 days since 2013. As of 13 November 2017 Joseph still owns at least 26,061 units of Mallinckrodt Plc stock.
You can see the complete history of Joseph Zaccagnino stock trades at the bottom of the page.
Joseph's mailing address filed with the SEC is McDonnell Boulevard, Hazelwood, Saint Louis County, Missouri, 63042, United States.
Over the last 11 years, insiders at Mallinckrodt Plc have traded over $29,853,069 worth of Mallinckrodt Plc stock and bought 2,559,592 units worth $174,429,961 . The most active insiders traders include & Co. Inc. Paulson, James E Deerfield Mgmt L.P.... és Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of $10,061. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth $9,495.
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
Mallinckrodt Plc executives and other stock owners filed with the SEC include: